Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced that it has granted equity inducement awards to two new employees as part of its 2022 Employment Inducement Award Plan. Approved by the Compensation Committee of the Board of Directors, these awards comply with Nasdaq Listing Rule 5635(c)(4). The new employees have been granted options to purchase a total of 325,000 shares of Terns common stock. These options, with a 10-year term, carry an exercise price of $3.56 per share, corresponding to the closing price on May 1, 2025. The vesting schedule spans four years, contingent upon the employees' continued service.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。